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Abstract
Background: The incidence of type 1 diabetes in Europe is increasing at a rate of about 3% per year and there is also an
increasing incidence throughout the world. Type 1 diabetes is a complex disease caused by multiple genetic and
environmental factors. Persistent organochlorine pollutants (POPs) have been suggested as a triggering factor for
developing childhood type 1 diabetes. The aim of this case-control study was to assess possible impacts of in utero
exposure to POPs on type 1 diabetes.
Methodology/ Principal Findings: The study was performed as a case-control study within a biobank in Malmo ¨, a city
located in the Southern part of Sweden. The study included 150 cases (children who had their diagnosis mostly before 18
years of age) and 150 controls, matched for gender and day of birth. 2,29,4,49,5,59-hexachlorobiphenyl (PCB-153) and the
major DDT metabolite 1,1-dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p9-DDE) were used as a biomarkers for POP
exposure. When comparing the quartile with the highest maternal serum concentrations of PCB-153 with the other
quartiles, an odds ratio (OR) of 0.73 (95% confidence interval [CI] 0.42, 1.27) was obtained. Similar results was obtained for
p,p9-DDE (OR 0.56, 95% CI 0.29, 1.08).
Conclusions: The hypothesis that in utero exposure to POPs will trigger the risk for developing type 1 diabetes was not
supported by the results. The risk estimates did, although not statistically significant, go in the opposite direction. However,
it is not reasonable to believe that exposure to POPs should protect against type 1 diabetes.
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Introduction
The incidence of type 1 diabetes in Europe and many other
parts of the world is increasing at a rate of about 3% per year
[1–5]. The increase is most pronounced among children in the
age-group of 0–4 years particularly in the high-incidence
populations of Sweden, Finland and UK [5–7]. Type 1 diabetes
is an autoimmune disease that is characterized by destruction of
insulin-producing pancreatic b-cells, resulting in a lack of or even
absence of insulin production and disturbed glucose homeostasis
[8]. It is a complex disease caused by multiple genetic and
environmental factors. It is evident that genetic factors play an
important role and the Human Leukocyte Antigen (HLA) class II
genotype on chromosome 6 is most strongly associated with an
increased risk [9]. However, children with high risk HLA
susceptibility generally progress to clinical disease in less than
10% [10]. The rapid increase and the wide spectrum of HLA
types among children with diabetes suggest that life-style or
environmental factors play a role in the pathogenesis. In addition,
the increasing incidence in populations moving from low to high
risk areas indicates that life-style or environmental modification is
part of the etiology [11]. Several studies support the hypothesis
that prenatal exposure to environmental factors are of impor-
tance. In this context, advanced maternal age, blood group
incompatibility between mother and child [12], maternal
enterovirus infections during pregnancy [13–14] and being born
with congenital rubella [15] are associated with an increased risk
of developing the disease later in life.
Among environmental pollutants suggested to trigger develop-
ment of type 1 diabetes in childhood is persistent organochlorine
pollutants (POPs), such as polychlorinated biphenyls (PCBs),
dioxins and the pesticide DDT. Circumstantial evidence support
that in utero exposure to POPs, have a triggering mechanism for
childhood diabetes. Both in vitro and in vivo studies in mice, rats
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2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), have been linked to
drastic reductions in cellular glucose uptake [16], and in rabbits
also a lowering of the insulin production [17]. There is also a
biologic plausibility for a link between dioxin-like compounds and
diabetes through interaction between aryl hydrocarbon receptor
and peroxisome proliferator-activated receptor mediated signal-
ing pathways [18–21]. Moreover, studies in mice predisposed to
development of autoimmune disease have shown that adminis-
tration of TCDD during gestation leads to exacerbated postnatal
autoimmunity [22]. In general, the doses used in animal studies
are higher as compared to the background levels that humans are
exposed to. On the other hand, the general population is most
often continuously exposed. However, there is only one
epidemiological study addressing the association between POP
and type 1 diabetes. In a small study on pregnant women, serum
levels of PCBs were 30% higher among those women with
diabetes (mostly type 1 diabetes) than among those without [23].
Since the study was cross-sectional, the causal relationship could
not be determined.
POPs have been released in our environment, since World War
II. These pollutants are accumulated particularly in highly rank
predators in the aquatic food chain. In Sweden, consumption of
fatty fish from the Baltic Sea is the major source of POPs, but also
dairy products and meat, contain these pollutants [24].
The aim of this case-control study was to investigate, by
comparing stored serum samples from delivery, if there is an
association between in utero exposure to POPs and risk for the child
to develop type 1 diabetes.
Materials and Methods
Study population and design
The vast majority of deliveries in the city of Malmo ¨, a city with
around 250.000 inhabitants situated in southern Sweden, take
place at the Malmo ¨ University Hospital maternity unit. Since
1970, venous blood samples from mothers and umbilical cord
blood samples from the newborns have routinely been collected.
Serum samples from approximately 70,000 deliveries are stored
frozen at 220Cu and cases and controls for this study were
selected from this serum bank. The study was performed in
accordance with the Declaration of Helsinki and approved by the
research Ethics Committee at Lund University. All participants
gave their verbal informed consent at the time blood samples were
collected. From the1960th to the 1990th written informed consent
was not used, at this time only verbal informed consent was used.
The women who were willing to donate a blood sample for
research were informed that the sample in the future could be used
for research. When this study took place the Ethic committee
approved the study and in addition we informed about the study in
the local newspaper and in this advertisement we gave the women
who ones had approved that their sample could be used for
research an opportunity to change their mind and by a phone call
tell us that the sample should be destroyed. The data were
analyzed anonymously.
Cases
Among children born from February 1970 to December 1990,
150 (82 boys and 68 girls, Table 1) have developed type 1
diabetes before year 2002. The vast majority (88%) of these cases
was diagnosed before the age of 18 years and almost all were
diagnosed and treated at the Department of Paediatrics at Malmo ¨
University Hospital. Patients who developed type 1 diabetes
between 18 and 27 years were identified using the Diabetes
Incidence Study in Sweden (DISS) registry [25]. Five cases had a
mother with type 1 diabetes (3%) and 8 a father with type 1
diabetes (5%).
Controls
For each case, a non-diabetic control was selected from
the serum bank and matched for gender and date of birth
(with the exception for two controls the differences were 69
months).
Biomarkers of exposure
In the present study 2,29,4,49,5,59-hexachlorobiphenyl (PCB-
153) has been used as a biomarker for POP exposure since PCB-
153 correlates very well (r=0.98) with total PCB concentrations in
plasma and serum from Swedish individuals [26–27], with the
TCDD equivalent (TEQ) in plasma from PCB (r=0.89). The
major DDT metabolite 1,1-dichloro-2,2-bis (p-chlorophenyl)-
ethylene (p,p9-DDE), which is detectable in a high proportion of
adult Swedes, was also used as a biomarker for POP exposure
[28].
Table 1. Background characteristics among 150 children
from the Southern part of Sweden who developed type 1
diabetes (cases) and 150 matched controls.
Cases Controls
n (%) n (%)
Birth year
a
1970–1975 47 (31) 45 (30)
1976–1980 26 (17) 28 (19)
1981–1985 36 (24) 36 (24)
1986–1990 41 (27) 41 (27)
Males
a 82 (55) -
Age at diagnosis (years)
,51 7 ( 1 1 ) -
5–9 43 (29) -
10–17 72 (48) -
$18 18 (12) -
Maternal age (years)
,20 6 (4.0) 9 (6.0)
20–24 40 (27) 33 (22)
25–29 57 (38) 65 (43)
30–34 33 (22) 28 (19)
.35 14 (9.3) 15 (10)
Primiparous, i.e. parity=1
b 66 (52) 57 (45)
Maternal smoking in early
pregnancy
c
10 (18) 15 (28)
Preterm (,37 weeks)
d 6 (4.7) 6 (4.8)
Birth weight ,2500 g
e 1 (0.8) 4 (3.2)
Birth weight .4500 g 8 (6.3) 3 (2.4)
aMatching variable.
bData missing for 22 cases and 24 controls.
cData missing for 93 cases and 96 controls (data only available from 1983 and
onwards).
dData missing for 22 cases and 24 controls.
eData missing for 22 cases and 26 controls.
doi:10.1371/journal.pone.0011281.t001
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PCB-153 and p,p9-DDE were analyzed as described in Rignell-
Hydbom et al. [29]. The compounds were extracted from 0.05 mL
aliquots of serum by solid phase extraction (Isolute ENV+; IST,
Hengoed, UK) using on-column degradation of the lipids and
analysis by gas chromatography mass spectrometry.
13C12-labeled
PCB-153 and
13C12-labeled p,p9-DDE were used as internal
standards. The relative Coefficient of Variation (CV), calculated
from 330 samples analyzed in duplicate at different days, were 10%
at 3 ng/mL for PCB-153 and 12% at 13 ng/mL for p,p9-DDE. The
quantification limits were 0.05 ng/mL for PCB-153 and 0.1 ng/
mL for p,p9-DDE. The analyses were part of a round-robin inter-
comparison program (University of Erlangen-Nuremberg, Ger-
many) and our results were within the tolerance limits.
Additional data collection
By linkage to the Swedish Medical Birth Register information
was obtained about parity, gestational length and birth weight
(Table 1). Information on maternal smoking in early pregnancy
was only available from 1983 and onwards, and was accordingly
missing for most of the material (63%).
Statistical analyses
By use of the sign test [30], we investigated whether the POP
exposure levels differed between the cases and the controls in a
systematic way. In addition, we performed separate analyses for
the children born between 1970 and 1980, and for the children
born between 1981 and 1990.
The association between the absolute levels of maternal POP
concentrations and the risk in the offspring to develop type 1
diabetes was evaluated by conditional logistic regression (using the
statistical software EGRET), given odds ratios (OR) as the risk
measure with 95% confidence intervals (CI). The exposure
variables (PCB-153 and p,p9-DDE) were categorized into quartiles
based on the distributions among controls. The lowest exposure
category was the reference category. We did also estimate p-values
for trend by including the categorized exposure variables as
continuous variables (coded 0, 1, 2 and 3) in the models. Due to
the relatively high correlation between PCB-153 and p,p9-DDE
(rs=0.63) concentrations we did not include these exposure
measures simultaneously in the models. We did, however, create a
trichotomized exposure variable based on PCB-153 and p,p9-DDE
concentrations. The three categories was defined as i) children
whose mothers had exposure levels of PCB-153 in the lowest
quartile and p,p9-DDE in the lowest quartile, ii) children whose
mothers had exposure levels of PCB-153 in highest quartile and
p,p9-DDE in the highest quartile, and iii) all other. Maternal age,
parity, preterm birth (,37 weeks), high birth weight (,4500 g),
and smoking habits in early pregnancy were all considered as
potential confounders.
Figure 1. The median maternal serum concentrations of PCB-153 from 1970–1990.
doi:10.1371/journal.pone.0011281.g001
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their type 1 diabetes diagnosed before the age of 5 years and the
cases who developed type 1 diabetes diagnosed after the age of 18
years with Mann-Whitney test. By definition, children who
developed type 1 diabetes after the age of 18 years had to be
born before 1984, and in this latter comparison we only included
children born before 1984.
Results
Exposure levels
The median maternal serum concentration of PCB-153 was
2.4 ng/mL (range 0.1, 11.4) in cases and 2.6 ng/mL (0.2, 7.2) in
controls. Among all children the exposure levels were significantly
(p,0.001) decreased over the study period (rs=20.47 and
rs=20.54, respectively; Figure 1).
The median maternal serum concentrations of p,p9-DDE were
9.2 ng/mL (0.5, 79) in cases and 9.6 ng/mL (0.9, 129) in controls.
As for PCB-153, the levels of p,p9-DDE decreased over time
(rs=20.60 and rs=20.68, respectively; Figure 2).
PCB-153 and type 1 diabetes
In the present study, all potential confounders showed very
weak and non-significant (all p-values .0.3) associations with type
1 diabetes. In addition, the distributions of these variables among
cases and controls were similar (Table 1). Accordingly, except for
the matching variables (gender and date of birth) we did not adjust
for additional variables in the conditional logistic regression
analyses.
When comparing the group with the highest maternal serum
concentrations of PCB-153 with the group with the lowest
concentrations, an OR of 0.64 (95% CI 0.32, 1.29) was obtained
(Table 2). The upper three exposure quartiles gave ORs below
unit i.e 1.0, although not statistically significant, when they were
compared with the lowest exposure quartile. In addition, there
were no statistically significant trend (p=0.17). When the upper
three exposure quartiles were merged into one group, and
compared with the lowest exposure quartile, an OR of 0.73
(95% CI 0.42, 1.27) was obtained, corresponding to a p-value of
0.27. The ORs were very similar when the analyses included only
male children (data not shown).
Out of the 150 cases, 85 had lower PCB-153 levels as compared
to their matched control, given a p-value of 0.07. There were no
systematic difference (p=0.47) for the early period (born 1980 or
earlier), whereas there was a statistically significant (p=0.04)
difference for the latter period (born 1981 or later), where 48 out
of the 77 cases had lower levels of PCB-153 as compared to their
matched control.
Figure 2. The median maternal serum concentrations of p,p9-DDE from 1970–1990.
doi:10.1371/journal.pone.0011281.g002
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As was observed for PCB-153, the upper three exposure
quartiles did all give ORs below unit when they were compared
with the lowest exposure quartiles (Table 2). However, there
were no statistically significant trend (p=0.29). When the upper
three exposure quartiles were merged into one group, and
compared with the lowest exposure quartile, an OR of 0.56
(95% CI 0.29, 1.08) was obtained, corresponding to a p-value of
0.08. The ORs were very similar when the analyses included
only male children (data not shown).
For p,p9-DDE exposure there were no systematic differences
between cases and controls when paired comparisons (by sign
test) were performed, irrespectively of study period inves-
tigated.
PCB-153 and p,p9-DDE and type 1 diabetes
The children whose mothers were categorized into the upper
PCB-153 quartile as well as in the upper p,p9-DDE quartile had a
non-significant decreased risk (OR 0.50, 95% CI 0.20, 1.25) of
developing type 1 diabetes as compared to children whose
mothers were categorized into the lowest PCB-153 quartile as
well as in the lowest p,p9-DDE quartile
Age at type 1 diabetes
The maternal levels of PCB-153 and p,p9-DDE did not differ
(p=0.80 and p=0.59, respectively) between the mothers whose
children had their type 1 diabetes diagnosed before the age of five
years (n=10) and the mothers whose children had their diabetes
after the age of 18 years (n=18).
Discussion
This study did not show what we expected; a higher risk of
type 1 diabetes in the offspring when the woman was exposed to
POPs during pregnancy. The hypothesis that in utero exposure to
POPs will trigger a development of type 1 diabetes was not
supported by our data. Actually, the trend was in the opposite
direction; with a higher POPs concentration in maternal serum,
the risk of diabetes in the offspring was lower. This raises the
question whether exposure to POPs have a protective effect.
However, we suggest an alternative explanation. In Sweden, fish
intake is associated with higher levels of POP biomarkers in
blood [31]. These biomarkers might, however, not only be a
proxy for the toxic compounds, but also for the essential long-
chain fatty acids eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) present in fatty fish [32]. EPA and DHA are
incorporated in the cell membranes and have anti-inflammatory
effects that might protect against type 1 diabetes. A Norwegian
study, comprising 545 children with type 1 diabetes and 1668
control subjects, found a significant relationship between intake
of cod-liver oil and a decreased risk of type 1 diabetes, possibly
through the effects of long-chain n-3 fatty acids [33]. Thus one
might speculate that PCB-153 as well as p,p9-DDE might act as
indicators for food intake of polyunsaturated fatty acids (PUFA),
which might protect against the risk of developing type 1
diabetes. The concentrations of POPs, especially PCB and
DDT, in fatty fish caught around the Swedish coast decreased
during the current study period [34]. In the present study there
was a decrease regarding serum POP concentrations in
maternal serum, which implies that the ratio between toxic
compounds and beneficial PUFAs might have changed over
time.
The foetal period is a vulnerable period for toxic substances
[35]. POPs can pass the placental barrier [36] and most POPs
have very long half-lives, five to ten years [36]. It is then
reasonable to believe that POP levels measured in serum women
reflect the in utero exposure in the fetus.
Due to the limited amount of serum available from the biobank,
the chemical analyses were restricted to CB-153 and p,p9-DDE
and we had no possibility to lipid adjust our samples. However, we
do not see this as a major problem due to the very strong
correlations (r.0.90) found between fresh and lipid adjusted
samples [27].
The access to stored serum samples collected at delivery
within a well-defined cohort is a major strength in the present
study. There are no reasons to believe that there is a selection
due to exposure. Moreover, by linkage to the Swedish Medical
Birth Register, which covers about 97–98% of all births in
Sweden since 1973, we had the possibility to collect infor-
mation about possible confounders. The study did accordingly
not lack information of known strong potential confounders,
although data for smoking habits were missing for the majority
of the participants. However, we can not exclude that other
factors created some statistical noise, thereby biasing the
results.
In conclusion, the results from the present study did not support
POP exposure to be a triggering factor to develop type 1 diabetes.
The risk estimates went in the opposite direction. In future studies
we recommend that biomarkers for food consumption, such as
PUFAs, should be analyzed to investigate the relation between
PUFAs and the risk of developing islet autoimmunity or type 1
diabetes among children.
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Table 2. Maternal serum concentrations of PCB-153 and p,p9-
DDE at delivery, and the risk for developing type 1 diabetes
among their infants.
Cases Controls OR 95% CI p for trend
PCB-153 (ng/mL) 0.17
,1.9 (ref) 47 39 1.00 -
1.9–2.6 39 36 0.85 0.45, 1.63
2.7–3.4 33 38 0.67 0.35, 1.31
.3.4 31 37 0.64 0.32, 1.29
p,p9-DDE (ng/mL) 0.29
,5.8 (ref) 47 36 1.00 -
5.8–9.6 36 40 0.58 0.28, 1.20
9.7–16.8 28 37 0.51 0.24, 1.07
.16.8 39 37 0.64 0.28, 1.46
Odds ratios (OR) and 95% confidence intervals (CI) were obtained with
conditional logistic regression analysis.
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